Cite
HARVARD Citation
Janku, F. et al. (n.d.). 418PDNCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. Annals of oncology. p. . [Online].